TALOPH(SH:600222)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥366,001,686.59, representing a 15.26% increase compared to ¥317,472,513.26 in the same period last year[4] - The net profit attributable to shareholders was ¥1,117,516.22, a significant decrease of 170.59% from ¥1,321,298.24 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥2,970,618.20, showing a 164.17% increase from a loss of ¥3,964,416.62 in the same period last year[4] - Total revenue for the first three quarters of 2021 reached ¥1,117,873,585.28, an increase of 15.8% compared to ¥965,315,174.14 in the same period of 2020[23] - Net profit for the third quarter of 2021 was ¥29,135,082.76, compared to ¥23,451,461.66 in the same quarter of 2020, representing a growth of 24.0%[24] - The company reported a total comprehensive income of ¥152,478,384.04 for the third quarter of 2021, compared to ¥209,585,308.49 in the same quarter of 2020, a decrease of 27.2%[25] Cash Flow and Liquidity - The net cash flow from operating activities increased by 227.22%, reaching ¥63,005,957.11 compared to ¥21,383,911.63 in the previous year[4] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 1,192,818,670.20, an increase of 19.5% compared to CNY 998,252,098.80 in the same period of 2020[27] - Net cash flow from operating activities in Q3 2021 was CNY 63,005,957.11, significantly up from CNY 19,255,063.59 in Q3 2020, representing a growth of 227.5%[28] - The ending cash and cash equivalents balance for Q3 2021 was CNY 536,222,847.19, compared to CNY 463,493,644.76 at the end of Q3 2020, reflecting a year-over-year increase of 15.7%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,857,651,202.83, reflecting a 13.82% increase from ¥3,389,394,715.08 at the end of the previous year[5] - Total liabilities as of Q3 2021 amounted to ¥2,133,844,838.86, compared to ¥1,858,823,901.11 in Q3 2020, indicating an increase of 14.8%[20] - The company's total assets increased to ¥3,857,651,202.83 in Q3 2021, up from ¥3,389,394,715.08 in Q3 2020, marking a growth of 13.8%[20] - The total liabilities amounted to approximately $1.86 billion, with a slight increase of $44.47 million compared to the previous period[32] Shareholder Equity - The equity attributable to shareholders increased by 11.57%, amounting to ¥1,621,639,527.76 compared to ¥1,453,415,199.81 at the end of the previous year[5] - The company's equity attributable to shareholders reached ¥1,621,639,527.76 in Q3 2021, up from ¥1,453,415,199.81 in Q3 2020, reflecting an increase of 11.6%[20] - Total equity reached approximately $1.53 billion, with the equity attributable to shareholders amounting to approximately $1.45 billion[32] Investments and Acquisitions - The company completed the acquisition of a 33.95% stake in Ta Long Health Industry Investment Co., Ltd., increasing its ownership to 80.40%, which allows for control over the company[5] - The company invested RMB 2,090,000 to acquire 95% of Zhengzhou Pairui Pharmaceutical Co., Ltd. to develop small molecule CDMO business[14] - The company established a wholly-owned subsidiary, Zhengzhou Weixian Pharmaceutical Technology Co., Ltd., with an investment of RMB 3,000,000 to enhance its drug research and registration capabilities[14] Inventory and Assets Management - The total inventory increased to RMB 404,567,769.44 from RMB 348,143,680.47, reflecting a rise of approximately 16.1%[18] - Long-term equity investments rose to RMB 40,678,587.06 from RMB 19,633,703.01, marking an increase of about 106.5%[18] - The company’s goodwill remained stable at RMB 286,492,789.75, unchanged from the previous period[18] Financial Standards and Compliance - The company adopted new leasing standards starting in 2021, which adjusted the financial statements accordingly, impacting the balance sheet figures[29] - The company adopted the new leasing standards effective January 1, 2021, which is not expected to significantly impact net profit, total assets, or net assets[33]